{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T04:23:27Z","timestamp":1697775807734},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10679,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1983,5]]},"abstract":"<jats:p>The plasma potassium responses to 1 week's treatment with metolazone 0.625 mg, 1.25 mg and 2.5 mg in combination with spironolactone 50 mg, and metolazone 2.5 alone were examined in a double\u2010blind, crossover study in twelve healthy subjects. Spironolactone attenuated the hypokalaemia induced by metolazone\u2013addition of spironolactone 50 mg to metolazone 2.5 mg raised plasma potassium by 0.18 mmol\/l (P less than 0.025). In the presence of spironolactone, a linear log metolazone dose\u2010 plasma potassium response relationship (P less than 0.01) was demonstrated. Spironolactone was unable to compensate fully for metolazone's hypokalaemic effect although in combination with metolazone 0.625 mg and 1.25 mg, plasma potassium concentration was maintained close to pretreatment levels. The human bioassay employed provided conveniently quantitative information which allows the rational development of a fixed dose diuretic\u2010spironolactone combination tablet.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1983.tb02092.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T17:12:55Z","timestamp":1343322775000},"page":"564-566","source":"Crossref","is-referenced-by-count":0,"title":["Use of a bioassay in healthy men to evaluate diuretic\u2010spironolactone combinations."],"prefix":"10.1111","volume":"15","author":[{"given":"GT","family":"McInnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JR","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RM","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IR","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JM","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"357","article-title":"Efficacy and safety of metolazone in renal failure and the nephrotic syndrome.","volume":"13","author":"BENNETT W.M.","year":"1973","journal-title":"J. clin. Pharmac."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1974162318"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92869-9"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976192177"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1973.03650070030005"},{"key":"e_1_2_1_7_1","article-title":"Dose\u2010response relationships for spironolactone in combination with a potassium wasting diuretic.","author":"McINNES G.T.","year":"1983","journal-title":"Clin. Pharmac. Ther."},{"key":"e_1_2_1_8_1","first-page":"149P","article-title":"Time course of urine electrolyte and plasma potassium responses to treatment with metolazone and spironolactone.","volume":"14","author":"McINNES G.T.","year":"1982","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_9_1","first-page":"594P","article-title":"Potassium\u2010sparing potency of prorenoate K relative to spironolactone.","volume":"14","author":"McINNES G.T.","year":"1982","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(69)90252-X"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1971125843"},{"key":"e_1_2_1_12_1","first-page":"401","article-title":"Factors influencing serum potassium in treated hypertension.","volume":"46","author":"RAMSAY L.E.","year":"1977","journal-title":"Quart. J. Med."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01119.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.75"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1983.tb02092.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1983.tb02092.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:35:15Z","timestamp":1697762115000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1983.tb02092.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1983,5]]}},"alternative-id":["10.1111\/j.1365-2125.1983.tb02092.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02092.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,5]]}}}